Minerva Neuroscie NERV

$2.20 -0.10 (-4.35%)

Valuation

Market cap
109,820,000
Revenue TTM
$0
Net income TTM
$-293,420,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
173,100
Avg volume
191,002
Day's range
$2.18 – $2.35
Shares out
47,748,000
Stochastic %K
7%
Beta
-0.10
Analysts
Sell
Price target
$10.33

Price

Company profile

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in...

Show more

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
617 600 7373
Website
https://www.minervaneurosciences.com
Address
1500 District Avenue, Burlington, United States

Latest news